People · Operator
Named in public records as an officer, director or promoter · active 2010–2021 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Woolsey Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $28.3M | $436.6M | 2020 |
| Remedy Pharmaceuticals, Inc. | — | Pharmaceuticals | Series A | $18.8M | $280.7M | 2010 |
| Critical Care Diagnostics, Inc. | — | Biotechnology | Seed | $2.6M | $114.0M | 2012 |
DAVID M. GELIEBTER at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside DAVID M. GELIEBTER on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| SVEN M. JACOBSON | 2 | 2 |
| SVEN JACOBSON | 1 | 2 |
| David Geliebter | 1 | 2 |
| James V. Snider | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.